Research landscape, thematic evolution, and translational insights of immune checkpoint inhibitor-induced colitis: a bibliometric analysis (2006-2025). [PDF]
Front ImmunolZheng H, Lai C, Liu F, Luo H.
europepmc +1 more source
Immune Checkpoint Inhibitors: efficacy, safety, and biomarkers - a systematic review. [PDF]
Front OncolIsmail H, Hassan A.
europepmc +1 more source
Influence of body composition on the efficacy of nivolumab plus ipilimumab for metastatic clear cell renal cell carcinoma. [PDF]
J Immunother CancerGrewal K +17 more
europepmc +1 more source
Clinical activity and safety of nivolumab in combination with ipilimumab in metastatic melanoma: findings from REALIPINIVO, a real-world study. [PDF]
Front ImmunolCaraglia F +26 more
europepmc +1 more source
Correction: Comparison of real-world efficacy and safety of nivolumab plus ipilimumab or pembrolizumab combined with platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer in a German population. [PDF]
Cancer Immunol ImmunotherWeber M +4 more
europepmc +1 more source
Incidence and Comparative Risk of Hematological Adverse Events Across Different Immune Checkpoint Inhibitors: A Network Meta-Analysis of Randomized Controlled Trials. [PDF]
CureusVajje J +7 more
europepmc +1 more source
Immune Checkpoint Inhibitor-Associated Immune-Mediated Nephropathy: A Real-World Pharmacovigilance Study. [PDF]
J Clin MedMutis Alan A +5 more
europepmc +1 more source
Advances in the treatment of cutaneous tumors: from conventional therapies to targeted and immunotherapeutic strategies. [PDF]
World J Surg OncolShen H, Wu H, He Z, Xiong S, Li R.
europepmc +1 more source